Abstract
Introduction
Reperfusion of an occluded coronary artery is the only known therapeutic strategy preventing myocardial necrosis if applied in time. Nevertheless, reperfusion itself can induce a certain damage, i.e. reperfusion injury. Clinically it may appear as reversible decrease of myocardial contrac-Ž .w x tility stunning 1,2 , or as reversible loss of endothelial w x function 3 . However, both deficits may persist in single cases, if microcirculatory perfusion is impaired for a pro-) Ž . Ž . Corresponding author. Tel. q49-89 5996402; Fax q49-89 5996378; E-mail u721101@sunmail.lrz-muenchen.de longed time, as indicated by low-reflow or no-reflow w x phenomena 4,5 . Ž . Polymorphonuclear granulocytes PMN which are recruited and activated in the reperfused myocardium can w x contribute to myocardial reperfusion injury in patients 6 , w x as well as in a variety of models in vivo 7-11 and in situ w x 12,13 . Two alternative mechanisms are considered relevant for PMN retention in microcirculatory beds. Capillary plugging of PMN as physical process is caused by narrowing of capillary lumina andror reduced leukocyte elasticity w x 14 . On the other hand, neutrophils may selectively inter- 16 . The adhesion process of PMN on endothelial cells generally follows w x a two-step pattern 17 , a slow movement of a leukocyte on Ž . the endothelial cell wall rolling and subsequent firm Ž .Ž w x. adhesion sticking for review see 18 Inhibition of the angiotensin I converting enzyme Ž . ACE , which represents a widely used pharmacologic intervention in patients with coronary artery disease, was beneficial against myocardial reperfusion injury in several w x distinct models [19] [20] [21] [22] [23] . ACE-inhibition has been shown to reduce bradykinin degradation, in turn stimulating nitric w x oxide synthase 24,25 . Since NO mitigates PMN adhesion w x in other vascular beds 26 , we wanted to investigate the cardioprotective potential of ACE-inhibition during postischemic reperfusion in an isolated heart model where the contribution of PMN to reperfusion injury can be distinguished from other sources of postischemic damage. To evaluate the effect, we assessed pre-and postischemic myocardial and endothelial function in terms of external heart work and endothelial nitric oxide release, respectively. In addition, we performed in situ fluorescence microscopy to characterize the precise localization and quantity of postischemically retained PMN. To determine the importance of NO, ACE inhibition was consistently Ž . compared with a nitric oxide synthase inhibitor NOLAG in further experiments.
Methods

Materials
Cilazaprilat, which was a gift of Hofmann-La Roche Ž . Basel, Switzerland , was used at 2 mM. Nitro-L-arginine Ž . NOLAG, Sigma Chemie, Deisenhofen, FRG was used at Ž . 10 mM, rhodamine 6G Sigma Chemie was used to label PMN. Percoll for PMN separation and fluorescein isothio-Ž . cyanate-dextran FITC dextran, MW 150 000 were purchased from Pharmacia Biotech AB, Uppsala, Sweden. Ž Monoclonal antibodies against CD15 Miltenyi, Cologne, . FRG were used for human PMN separation, whereas CD11b analysis was performed with monoclonal antibod-Ž . ies from Exalpha Boston, MA .
PMN preparation
Homologous
Ž . For in situ microscopy experiments, PMN guinea pig w x were isolated as previously described 27,28 . Using HES sedimentation, Percoll separation and red cell lysis with distilled water, a pellet of at least 95% pure, 99% viable PMN was obtained. PMN were incubated with rhodamine Ž . Ž 6G 0.005%, 10 min , counted Coulter Counter ZM with . Channelyzer, Coulter Electronics, King, NC, USA , and Ž
6
. adjusted to the required cell content per ml 10 = 10 rml .
Human
In order to study PMN activation by flow-cytometrical surface analysis, a heterologous source of PMN was used, because no guinea pig antibody against CD11b was available to the best of our knowledge. Human PMN were isolated from peripheral venous blood of healthy volunteers by magnetic bead separation, as described elsewhere w x 29 . Briefly, purification of neutrophils from 10 ml human Ž . blood EDTA 0.1% was achieved by magnetic separation of cells previously labelled with a CD15 antibody carrying Ž iron microbeads Miltenyi Biotech, Bergisch Gladbach, . Ž FRG . Cells were analyzed by flow cytometry FACScan, . Becton Dikinson, San Jose, CA, USA and proved to be 99% PMN. Cells were resuspended in Tyrode's solution Ž .
6 pH 7.40 , counted and diluted to 10 = 10 cellsrml. As established in an earlier study, the cells prepared by these two techniques are not prestimulated and of comparable w x reactivity 29 .
Heart preparation
The care of the animals and all experimental procedures conform with the Guide for the Care and Use of Laboratory Animals. Guinea pig hearts were isolated and perfused Ž as previously described. Briefly, animals male, 200-250 . Ž . g were anesthetized Ketanest 200 mgrkg body weight and decapitated. The hearts were arrested with cold saline and removed quickly from the thorax. The aorta was canulated and retrogradely perfused with a modified Krebs-Henseleit buffer gassed with 97% O and 3% CO 2 2 Ž . 378C, pH 7.40 .
Ž . For microscopic evaluation Langendorff preparation caval, azygos and pulmonary veins were ligated. Retrograde perfusion was maintained throughout the experiment and in situ microscopic period.
The working heart preparation was performed, as previw x ously described 30 . The caval and azygos veins were ligated. Pulmonary venous entry was used for a canula which, in the working mode of the heart, provided orthograde access for the perfusate. In the perfusion appara-Ž tus it was possible to switch between non-working Lan-. gendorff mode and working heart mode. External heart work was calculated as the sum of pressure-volume work Ž . developed aortic pressure= cardiac output and acceleraw x tion work 29 .
Experimental protocols
Immediately after canulation, hearts were perfused at Ž . constant aortic pressure 80 cm H O for 5 min to finish 2 preparation. At this point, hearts were assigned either to microscopic evaluation or to functional studies including determination of external heart work, nitric oxide release and leukocyte activation.
In experiments assessing external heart work, pressure Ž volume work was performed preload 12 cm H O, after- Ž . After ischemia 15 min, 378C , hearts were initially reper-Ž fused in the non-working Langendorff mode 5 mlrmin, . 20 min before a second period of external heart work at the given conditions was begun.
For microscopic evaluation, perfusion was continued at Ž constant coronary flow of 5 mlrmin for 30 min see Fig. . 1B . Usually, global ischemia was next imposed for 15 min, during which hearts were immersed in warm per-Ž . fusate 378C, pH 7.40 . Thereafter, reperfusion was started, again at 5 mlrmin, lasting for 5 min in all experiments. PMN were applied when reperfusion was started and recovered in the coronary effluent for 3 min for further analysis. Cold cardioplegic solution was then infused to arrest the heart. After being placed on a stage displaying the left ventricle area to the microscope, FITC-infusion was begun.
Most experimental series involved 10 hearts, 5 of each used in parallel experiments for either microscopic or functional evaluation. Time matched 'control' experiments were performed without ischemia, 10
7 PMN being applied after 45 min of perfusion. In the 'ischemia' series PMN were infused in the first min of reperfusion after 15 min of ischemia. In addition, one working heart group was subjected to ischemia without PMN infusion. To assess the Ž . role of endogenous NO, cilazaprilat 2 mmolrl and nitro-Ž . L-arginine NOLAG, 10 mmolrl were added to the per-Ž . fusate in order to stimulate indirectly or inhibit NO synthase activity in experiments including ischemia.
Nitric oxide release
In working heart experiments, a nitric oxide sensitive, Ž . microtip probe WPI, Sarasota, FL, USA was placed into the pulmonary artery directly behind the pulmonary valve, the tip of the NO sensor being inserted into a T-tube. Isothermal conditions were achieved by immersing preparations in Tyrode's solution at 378C. Validation of the probe recording in the coronary effluent was performed using bradykinin to generate NO by the endothelium, and Ž . erythrocyte-borne hemoglobin hematocrit 5% to se-Ž . quester NO data not shown . Reproducible stimulation and suppression of the signal to zero were observed, respectively.
Considerable variability of basal release of NO between Ž . hearts during preischemic volume constant perfusion L 1 was found in all groups. Comparability of volume constant Ž . perfusion and working heart mode different flow rates was achieved by calculating NO release per minute per g dry weight of the hearts from the concentration data. Postischemic NO release is given in percent of preischemic values.
Fluorescence microscopy
For the purpose of in situ microscopy hearts were Ž arrested by cold cardioplegic solution potassium 28 . mmolrl . Thereafter they were placed on a specially designed microscopic stage holder, the surface of the left Ž ventricle being exposed to a microscope Ploemopak, Leitz, . Ž Wetzlar, FRG with a 10-fold objective L10, 0. . tionremission spectra: 450-490r)515 nm . The distribution of PMN was studied under a rhodamine 6G selective Ž N filter block Leitz, excitationremission spectra: 515-2 . 560r)580 nm .
This method allowed for localization of PMN with respect to the vascular lumen. Capillary plugging was assessed by counting PMN in regions devoid of venules. 5 fields with an area of 1.2 mm 2 each were studied per heart. Postcapillary venular adhesion was observed in venules of Ž . 10-50 mm diameter small venules, n s 8-10 per heart . Ž In addition, venules of 50-300 mm diameter large venules, . n s 4-5 per heart were investigated. Fig. 2 demonstrates FITC and rhodamine fluorescence of an epicardial surface of a postischemic heart, showing substantial leukocyte adhesion in venules, but not in arterioles.
Flow cytometry analysis
To further assess the degree of activation induced during coronary passage, PMN were analyzed in a flow Ž cytometer FACScan, Becton Dickinson, San Jose, CA, . Ž. USA using a phycoerythrin PE fluorescence-labelled Ž . monoclonal CD11b-antibody Moab which bound to the PMN epitope CD11b, part of the heterodimeric adhesion Ž . molecule CD11brCD18 MAC-1 . Forwardscatter analysis and gating of the PMN range provided analysis of a homogeneous PMN population. Isotype controls with a Ž . nonbinding, fluorescence labelled Moab anti-mouse IgG1 served to determine nonspecific binding and background fluorescence. Activation of PMN was expressed in relation to the basal values before coronary passage. Data analysis of 10 000 events was performed with Lysis II software on a Hewlett Pakard system.
Statistical methods
The results are given as mean " SEM. Statistical analysis was performed with one way analysis of variance Ž . ANOVA . Whenever a significant effect was obtained with ANOVA, we performed multiple comparison tests Ž between the groups using Dunn's test Sigmastat statistical . program . Differences between groups were considered significant for p -0.05.
Results
Since beneficial effects of ACE-inhibitors have been demonstrated following myocardial hypoperfusion in vivo, we studied the effects of cilazaprilat on PMN dependent myocardial reperfusion injury.
Functional reperfusion injury
Coronary and myocardial function
At a concentration of 2 mM, cilazaprilat evoked no Ž . change in coronary flow CF or coronary perfusion pres-Ž . Ž . sure CPP preischemically Table 1 , in contrast to NO-LAG which, at 10 mM, elevated CPP. After ischemia, CPP first decreased during postischemic dilation, before rising above preischemic values in all groups. Fittingly, CF in W 2 was significantly suppressed vs. the preischemic value in Ž . all groups Table 1 . The same tendency existed in the presence of cilazaprilat, excluding a major hemodynamic effect of the drug. In contrast, NOLAG blunted the postischemic dilation and decreased CF in W more extensively 2 than PMN alone.
Values of external heart work prior to ischemia for the various experimental groups did not differ significantly Ž . Table 1 . Application of a PMN bolus without ischemia caused only a slight detriment of external heart work Ž . Control PMN, Fig. 3 . After ischemia alone, recovery of EHW deteriorated to 67 " 5% of the initial value. Ischemia and a PMN bolus acted synergistically, reducing recovery of EHW to 39 " 6%. This level was further Ž . decreased to 29 " 6% in the presence of NOLAG 1 mM . If the concentration of NOLAG was increased to 10 mM, no recovery could be measured due to ventricular fibrilla-Ž . tion and pump failure. Cilazaprilat 2 mM , however, Ž counteracted the detrimental effects of PMN without 64 " . Ž . 4% or in the presence of NOLAG 1 mM, 41 " 3% , whereas it did not influence the recovery of reperfused Ž . hearts not confronted with PMN 65 " 4% recovery .
Thus, postischemic myocardial performance was related to the absence or presence of PMN. Cilazaprilat effectively prevented PMN-induced loss of function, NOLAG augmented it. 
Studies on nitric oxide release
Release of nitric oxide is a specific feature of the endothelium, regulating vascular resistance. We investigated endothelial integrity by measuring NO release of the whole coronary system. Isolated guinea pig hearts performing pressure-volume work prior to ischemic challenge Ž . W released NO into the coronary effluent at variable, 1 Ž . but not significantly different rates Table 1 . The concentration approximated 2-3 mM. Preischemic 'basal' nitric Ž . L was markedly lower than during work W , Table 2 . 1 1 Surprisingly, cilazaprilat had no discernible effect on preischemic NO release, as already suggested by coronary Ž . hemodynamics Table 1 . Since no in situ calibration of the NO-flow probe was possible in the presence of NO-LAG, no quantitative data were obtained for these experimental groups. In hearts receiving PMN without preceding Ž . ischemia controlq PMN , the capability to form NO was only slightly attenuated over time, the difference between Ž L and L amounting to 0.5 nmolrminrg results not 1 2 .
shown .
To correct for differences of NO release due to the mode of perfusion, postischemic values of L or W in 2 2 Fig . 4 are given in percent of the preischemic values Ž . obtained in the same mode L or W . In hearts subjected 1 1 to ischemia, a transient increase in NO release after 5 min of reperfusion was displayed in most groups, which was Ž . most prominent in the presence of cilazaprilat Fig. 4 . Although the postischemic increase in NO release lasted only a few minutes, it was during this period that PMN application into the coronaries occurred in the present experiments. Over the subsequent 20 min, NO release decreased by 30% on average. The drop was found to be Ž most pronounced in the PMN group 46 " 1% of the . preischemic value . This leukocyte-dependent effect was prevented by cilazaprilat, whereas no effect of cilazaprilat was detected in hearts not subjected to PMN infusion. Ž Experiments with inhibition of NO synthases NOLAG, 10 . mM displayed neither an increase after 5 min nor a Ž . decrease after 20 min of reperfusion data not shown . However, the lack of reaction of the probe after challenge with an erythrocyte bolus suggested that no endogenous NO formation was taking place under this condition anyway. Ž In work phase 2, hearts released only about half 55 " . Ž . 0.5% of the NO detected in W Fig. 4 . Hearts in the 1 ischemia PMN group released less nitric oxide than in the absence of PMN. Pretreatment with cilazaprilat prevented this effect of PMN but did not restore postischemic NO release to the preischemic level. The relative conservation of the postischemic NO release through cilazaprilat was Ž not related to a higher level of NO preischemically Table  . 1 .
Leukocyte adhesion and actiÕation after ischemia
Capillary plugging
PMN can be trapped in the microcirculatory system through plugging in capillaries, where the vessel diameter is reduced to about 10 mm and less. As shown in one Ž . example hesion to more than 13-fold the control level. Fig. 8A and B show two representative examples of postcapillary adhe-Ž . sion in small venules with either cilazaprilat Fig. 8A or Ž . NOLAG Fig. 8B added to the perfusate.
Large
Õenules. Very few PMN were localized in Ž PMN per mm surface area , although no significant effect could be obtained. NOLAG, in contrast, tended to increase postischemic PMN adhesion in the large venules to 48 " 9 2 Ž . PMN per mm surface area Fig. 7 . Taken together, these findings suggest that postcapillary adhesion rather than capillary plugging accounts for increased coronary PMN retention after ischemia in the present model. ACE-inhibition reduces, while NOLAG increases adhesion, indicating an antiadhesive effect of nitric oxide.
Leukocyte actiÕation
Activation of human leukocytes was further analyzed by quantifying CD11b surface expression. As shown in Ž . Fig. 9 , PMN of control experiments without ischemia displayed almost no difference in CD11b surface expression before and after coronary passage. Postischemically, however, a 2.6 fold elevation of CD11b expression had occurred on PMN emerging from the coronary system. When cilazaprilat was present, this increase in CD11b-associated fluorescence intensity was completely abolished, whereas NOLAG further enhanced CD11b expression. These findings indicate that cilazaprilat prevents activation and subsequent postcapillary adhesion, most likely through a nitric oxide mediated mechanism.
Discussion
Early implementation of ACE inhibition after myocardial infarction has proven beneficial in several models w x 19-23 . In search of a possible 'local' action to explain this effect, we have previously found ACE-inhibitors to mitigate postischemic functional damage in saline-perfused hearts via a bradykinin and, ultimately, nitric oxide mediw x ated pathway 31 . NO, in turn, is known to mitigate adhesion of PMN in various vascular beds. Since PMN strongly exacerbate post-ischemic damage in the isolated w x heart model 27,28,31 , we set out to investigate the simultaneous occurrence and interdependence of four phenom-Ž . ena: First, the ability of an ACE inhibitor cilazaprilat to alleviate postischemic loss of myocardial performance induced by PMN, as opposed to the action of an inhibitor of Ž . NO-synthase nitro-L-arginine . Second, the actual effect of these interventions on postischemic coronary release of nitric oxide. Third, the corresponding changes in PMN adhesion according to specific localization in capillaries, small venules and collecting veins. Fourth, PMN activation during coronary passage in post-ischemic hearts in the presence of cilazaprilat or nitro-L-arginine.
Influence of ischemia and reperfusion
As a result of ischemia and reperfusion alone, isolated hearts suffered from compromised external heart work Ž . Fig. 3 , i. e. myocardial stunning, and a general decline in Ž . production of NO Fig. 4 . Both phenomena were aggravated by application of PMN during reperfusion. Reactive oxygen species play a crucial role in this type of reperfuw x sion injury, as shown by others 32 as well as in our w x model 27,28 . Beyond an inherent detrimental effect on cellular processes, reactive oxygen species may enhance interactions between endothelium and PMN by externalizaw x tion of stored P-selectin and PAF 29,33 as well as by activation and translocalization of the leukocyte receptor Ž .w x Mac-1 CD11brCD18 34 . The latter parameter was the Ž . one we chose to observe Fig. 9 . Indeed, we found CD11b expression to be markedly elevated on PMN after passage through the coronary system of post-ischemic hearts. These effects may explain the fast and significant rise of venular leukocyte adhesion immediately after resumption of coronary perfusion, a time at which de novo synthesis of adhesion molecules cannot yet have taken place. We cannot rule out a contribution of plugging leukocytes, which Ž . has approximately doubled postischemically 
Influence of ACE-inhibition on PMN dependent reperfusion injury
Several studies have shown a cardioprotective effect of ACE-inhibition after limited ischemia in vivo and in situ w x 19-23 . However, this work for the first time presents direct microscopic observations that ACE-inhibition by cilazaprilat can acutely reduce ischemia-induced PMN adhesion and activation in the coronary venules independent of any coronary hemodynamic influence. In parallel experiments, cilazaprilat was capable of blunting PMN depen-Ž . dent loss of myocardial external heart work and endothe-Ž . lial function reduced production of NO .
In the presence of the ACE-inhibitor ramiprilat, Schoelkens and coworkers found an increase in bradykinin concentration immediately after ischemia in isolated rat w x hearts 35 . Decreased bradykinin degradation due to ACE inhibition leads to a stimulation of endothelial nitric oxide w x synthase 31 . In this context it is important to point out that NO may act as an antioxidant and radical scavenger, which may interfere with the reperfusion-induced release of oxygen free radicals and, thus, prevent subsequent w x activation of endothelial cells and PMN 36 . The dependence on NO is made even more probable by the fact that cilazaprilat does not exert a radical scavenging effect itself Ž . w x data not shown , in contrast to e.g. captopril 37 . With Ž . the concentration of cilazaprilat used 2 mM , no effects were seen on recovery of external heart work during cell-free reperfusion, as opposed to findings with higher w x concentrations of a similar drug 24 . The negative effect of NOLAG on myocardial recovery is counteracted by Ž . cilazaprilat Fig. 3 suggesting that in fact cilazaprilat at Pennsylvania State University on February 21, 2013 http://cardiovascres.oxfordjournals.org/ Downloaded from ( )really does activate nitric oxide synthase. Interestingly, NO release was maintained by cilazaprilat at a higher level even after PMN application, i.e., the time at which adherent PMN produce tissue damaging radicals and oxidants.
How does the observed impact of cilazaprilat on myocardial and endothelial recovery relate to PMN retention of the hearts? A multitude of factors is able to change the balance of pro-and antiadhesive behaviour of coronary w x endothelial cells, notably NO 26 . In the presence of cilazaprilat, we observed slightly increased nitric oxide release during early reperfusion, the period in which PMN Ž . were injected Fig. 4 . Indeed, PMN, given in the early reperfusion, adhered less in the presence of cilazaprilat Ž . Fig. 7 , while, in contrast, capillary plugging was barely Ž . influenced Fig. 6 . At this point, however, it cannot be ruled out that nitric oxide formation in the presence of cilazaprilat has additional, indirect effects inhibiting proadhesive mediators formed during reperfusion, e.g. endothew x lin-1 38,39 .
Since NO release from the whole intact heart is a 'net' effect of nitric oxide production and consumption, the local increase of NO might have been higher but, in part, consumed by oxygen free radicals. The crucial importance of NO for leukocyte adhesion in our model is demonstrated by application of NOLAG, which increased adhe-Ž . sion and activation of PMN Figs. 8 and 9 . NOLAG is a nonspecific NO synthase inhibitor which affects endothe-Ž . Ž . lial eNOS and inducible nitric oxide synthase iNOS . However, in primary cultured endothelial cells from isolated rat hearts, we could not detect iNOS by Western Ž . blotting data not shown . Therefore NOLAG most likely affects the eNOS, the same enzyme which is activated in the presence of cilazaprilat.
Conclusions
In summary, we have investigated the influence of ACE-inhibition on PMN adhesion and myocardial and endothelial function after a PMN bolus given early in reperfusion of isolated hearts. Cilazaprilat mitigated postischemic increase in PMN adhesion, foremost in postcapillary venules. Concomitantly, PMN-induced loss of external heart work and reduction of endothelial nitric oxide release were prevented by cilazaprilat. ACE-inhibition also prevented activation of PMN during passage of the coronary system of postischemic hearts. Inhibition of NO-synthase caused the exact opposite in each case. Thus, the protective effects of ACE inhibition may well be mediated by the oxygen radical scavenging ability of NO and evolve from reduced adhesion of PMN in the presence of NO.
The findings of the present study underscore the importance of leukocyte adhesion and activation after ischemia. Pharmacological interventions aimed at reducing leukocyte induced reperfusion injury may well benefit those patients who already suffer from compromised myocardial contractility. Recent clinical investigations showing leukocyte activation in man as a potential risk factor of recurrent w x coronary events enforce this approach 40 .
